XERS vs LCTX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
XERS Captures Institutional Edge (3โ1 Pillars ยท 4โ6 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Xeris Biopharma Holdings, Inc. Common Stock (XERS) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while LCTX counters with relative strength in Valuation. Fundamentally, XERS trades at 62.3x Forward P/E with 12.7% operating margin (+44.2% YoY revenue) versus LCTX at 30.7x Forward P/E and -280.3% operating margin (-61.0% YoY). In options structure, XERS sits in SURGE (12th %ile IV; Dealer Gamma Walls on Pro) against LCTX sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | XERS Revenue | LCTX Revenue | XERS Op. Margin | LCTX Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $0M | N/A | -837.9% | LCTX |
| FY2019 | N/A | $0M | N/A | -1106.0% | LCTX |
| FY2020 | $20M | $0M | -414.5% | -1448.4% | XERS |
| FY2021 | $50M | $0M | -232.2% | -1133.6% | XERS |
| FY2022 | $110M | $10M | -74.3% | -153.2% | XERS |
| FY2023 | $160M | $10M | -26.8% | -276.5% | XERS |
| FY2024 | $200M | $10M | -16.6% | -226.1% | XERS |
| FY2025 | $290M | $10M | 8.5% | -251.6% | XERS |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | XERS | LCTX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.1B | $212.1M | Larger Scale | XERS |
| Trailing P/E Ratio Valuation | 86.2x | 30.7x | Lower Multiple | LCTX |
| Forward P/E Ratio Valuation | 62.3x | 30.7x | Lower Multiple | LCTX |
| Revenue Growth (YoY) Growth | +44.2% | -61.0% | Higher Growth | XERS |
| Operating Margin (TTM) Profitability | 12.7% | -280.3% | Higher Margin | XERS |
| Net Profit Margin Profitability | -1.8% | 16.2% | Higher Margin | LCTX |
| Return on Equity (ROE) Capital Efficiency | -27.1% | 4.3% | Higher ROE | LCTX |
| 52-Week Range Position Momentum | 94% ($5โ$17) | 4% ($1โ$2) | Stronger Trend | XERS |
| Beta / 30D Volatility Risk Regime | -0.03ฮฒ ยท 104% Vol | 1.36ฮฒ ยท 79% Vol | Lower Realized Risk | LCTX |
| Unified Institutional Score Composite Signal | 36.5 / 100 (SELL) | 58.9 / 100 (HOLD) | Higher Composite | LCTX |